Insulet Company Insiders

PODD Stock  USD 288.73  2.78  0.95%   
Insulet employs about 3.9 K people. The company is managed by 30 executives with a total tenure of roughly 54 years, averaging almost 1.0 years of service per executive, having 130.0 employees per reported executive. Evaluation of Insulet's management performance can provide insight into the firm performance.
James Hollingshead  CEO
CEO President
Eric Benjamin  President
Senior Vice President R&D, New Product Development and Commercialization
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in consumer price index.
For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.

Insulet's latest congressional trading

Congressional trading in companies like Insulet, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Insulet by those in governmental positions are based on the same information available to the general public.
2025-09-12Representative Ro KhannaAcquired Under $15KVerify
2025-08-13Senator Markwayne MullinAcquired Under $15KVerify
2025-08-11Senator Markwayne MullinAcquired Under $15KVerify
2025-07-30Senator Markwayne MullinAcquired Under $15KVerify
2025-07-29Senator Markwayne MullinAcquired Under $15KVerify
2024-04-18Senator Tina SmithAcquired $50K to $100KVerify
2024-01-25Senator Markwayne MullinAcquired Under $15KVerify
2020-04-16Senator Tina SmithAcquired $250K to $500KVerify
2020-04-15Senator Tina SmithAcquired $250K to $500KVerify
2018-09-19Senator Tina SmithAcquired $250K to $500KVerify
2018-09-18Senator Tina SmithAcquired $15K to $50KVerify
2018-06-11Senator Tina SmithAcquired $100K to $250KVerify
2018-06-10Senator Tina SmithAcquired $100K to $250KVerify
2018-03-06Senator Tina SmithAcquired $100K to $250KVerify
2018-03-05Senator Tina SmithAcquired $100K to $250KVerify

Insulet Management Team Effectiveness

The company has return on total asset (ROA) of 0.0874 % which means that it generated a profit of $0.0874 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1968 %, meaning that it created $0.1968 on every $100 dollars invested by stockholders. Insulet's management efficiency ratios could be used to measure how well Insulet manages its routine affairs as well as how well it operates its assets and liabilities.

Insulet Workforce Comparison

Insulet is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 273,727. Insulet claims roughly 3,900 in number of employees contributing just under 2% to equities under Health Care industry.
The company has Profit Margin (PM) of 0.1 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.17 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.17.

Insulet Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Insulet insiders, such as employees or executives, is commonly permitted as long as it does not rely on Insulet's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Insulet insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Insulet Notable Stakeholders

An Insulet stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Insulet often face trade-offs trying to please all of them. Insulet's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Insulet's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
James HollingsheadCEO PresidentProfile
Ashley McEvoyPresident CEOProfile
Eric BenjaminSenior Vice President R&D, New Product Development and CommercializationProfile
John KapplesSenior Vice President General Counsel, SecretaryProfile
Wayde McMillanCFO, Executive Vice PresidentProfile
Charles AlpucheSenior Vice President Global Manufacturing and OperationsProfile
Michael SpearsSenior Vice President Quality, Regulatory, and Clinical AffairsProfile
Flavia PeaseExecutive CFOProfile
Ana ChadwickExecutive CFOProfile
Mark FieldSenior CTOProfile
Patricia DolanVP SecretaryProfile
Philip HildaleSenior CareProfile
Andrew IsaacsonSenior DevelopmentProfile
Laetitia CousinQuality AffairsProfile
Carolyn SleethSenior ManagerProfile
Dan ManeaSenior OfficerProfile
Bret ChristensenChief Commercial OfficerProfile
June LazaroffSenior RelationsProfile
Deborah CPAVice RelationsProfile
Lisa DavisSenior OfficerProfile
Clare TrachtmanVice RelationsProfile
Patrick CrannellSenior ManagerProfile
Michael CPAAdvisorProfile
Prem SinghSenior OperationsProfile
John JDSenior CounselProfile
Amit GulianiInterim EngineeringProfile
Angela WiczekSenior CommunicationsProfile
Lauren BuddenChief VPProfile
Shacey PetrovicChief Commercial OfficerProfile
Trang LySenior OfficerProfile

About Insulet Management Performance

The success or failure of an entity such as Insulet often depends on how effective the management is. Insulet management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Insulet management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Insulet management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. Insulet Corp operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2300 people.
Please note, the presentation of Insulet's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Insulet's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Insulet's management manipulating its earnings.

Insulet Workforce Analysis

Traditionally, organizations such as Insulet use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Insulet within its industry.

Insulet Manpower Efficiency

Return on Insulet Manpower

Revenue Per Employee531.2K
Revenue Per Executive69.1M
Net Income Per Employee107.3K
Net Income Per Executive13.9M
Working Capital Per Employee349.5K
Working Capital Per Executive45.4M

Complementary Tools for Insulet Stock analysis

When running Insulet's price analysis, check to measure Insulet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insulet is operating at the current time. Most of Insulet's value examination focuses on studying past and present price action to predict the probability of Insulet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insulet's price. Additionally, you may evaluate how the addition of Insulet to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing